ExamFinch.com My Study

Study guide

Neuromuscular Blockade & Monitoring

Practice this exam

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Neuromuscular Blockade & Monitoring

Key Takeaways Explain This Topic AI

Neuromuscular blockade supports selected intubation, ventilatory, shivering, and pressure-control goals; use the minimum effective exposure.

Provide and maintain adequate analgesia and hypnosis before paralysis because NMBAs do not supply either.

Cisatracurium relies predominantly on Hofmann elimination; temperature and pH can affect duration even when organ clearance is less important.

Rocuronium and vecuronium can have prolonged effects with organ dysfunction; monitoring and recovery assessment are essential.

Use clinical effect and peripheral nerve monitoring together; TOF alone does not establish adequate sedation or an identical dose target in every patient.

Last updated: October 2026

Neuromuscular Blockade & Monitoring

Neuromuscular blocking agents ( N M B A s NMBAs NMB A s ) eliminate skeletal muscle contraction by competitively antagonizing nicotinic acetylcholine receptors ( n A C h R s nAChRs n A C h R s ) at the neuromuscular junction. In neurocritical care, chemical paralysis is never a routine sedative substitute. It represents an advanced, high-risk intervention reserved for specific physiologic crises where skeletal muscle activity directly threatens cerebral perfusion or systemic oxygenation. Because N M B A s NMBAs NMB A s cross neither the blood-brain barrier nor the threshold of sensory perception, paralyzed patients retain full consciousness, auditory perception, pain processing, and memory unless deeply anesthetized.

Specific Neuro-ICU Indications

Refractory Intracranial Hypertension: Indicated in Tier 2 or Tier 3 management of elevated I C P ICP I CP refractory to analgesia, deep sedation, and osmotherapy. Paralysis eliminates coughing, endotracheal tube bucking, chest wall rigidity, and Valsalva maneuvers, immediately reducing intrathoracic and central venous pressures, facilitating cerebral venous outflow through the internal jugular veins, and reducing I C P ICP I CP .

Shivering Suppression in Targeted Temperature Management (TTM): Shivering is an innate thermoregulatory reflex that increases systemic oxygen consumption and cerebral metabolic rate of oxygen ( C M R O 2 CMRO_2 CMR O 2 ​ ) by up to 100 % to 200 % 100\%\text{ to }200\% 100% to 200% , generates intense lactic acidosis, and spikes I C P ICP I CP . While surface counter-warming, buspirone, and magnesium sulfate are first-line anti-shivering measures, continuous N M B A NMBA NMB A infusions are indicated when shivering breaks through.

Severe Ventilator Dyssynchrony & ARDS: Neuromuscular blockade improves chest wall compliance, eliminates breath stacking, prevents patient-ventilator asynchrony, and reduces barotrauma and volutrauma in patients with concurrent neurogenic pulmonary edema or severe A R D S ARDS A R D S .

Refractory Status Epilepticus (Intubation & Metabolic Stabilization): During explosive motor status epilepticus, N M B A s NMBAs NMB A s may be required during rapid sequence intubation to abolish peripheral convulsions, manage severe lactic acidosis, and prevent hyperkalemic rhabdomyolysis.

Warning

Paralysis in Status Epilepticus Eliminates Motor Signs but NOT Brain Seizures! Peripheral muscle paralysis abolishes observable convulsions while continuous, destructive electrographic seizure activity persists in the cerebral cortex. Sustained electrographic status epilepticus continues to deplete cellular ATP, generate excessive excitotoxic glutamate, and cause irreversible neuronal necrosis. Continuous electroencephalography ( c E E G cEEG c EEG ) is mandatory whenever an N M B A NMBA NMB A is administered to a patient with status epilepticus.

  • Pharmacology of Non-Depolarizing NMBAs Non-Depolarizing Neuromuscular Blockers in Neurocritical Care
  • ├── Benzylisoquinolinium Class

│ └── Cisatracurium: Organ-independent Hofmann elimination, no histamine release, choice in renal/hepatic failure

  • └── Aminosteroid Class
  • ├── Rocuronium: Rapid onset (60-90 s), hepatic/biliary clearance, sugammadex reversible
  • └── Vecuronium: Intermediate onset, active 3-hydroxy metabolite accumulates in AKI
  • Cisatracurium (Benzylisoquinolinium)

Mechanism & Elimination: Cisatracurium is an R R R -cis isomer of atracurium that undergoes Hofmann elimination —a non-enzymatic, spontaneous chemical degradation occurring at physiologic temperature and blood p H pH p H —alongside non-specific plasma ester hydrolysis. It does not rely on renal excretion or hepatic clearance mechanisms.

Metabolites: Hofmann degradation yields laudanosine and a monoquaternary acrylate metabolite. Although massive concentrations of laudanosine have caused CNS excitation and seizures in animal models, laudanosine concentrations during therapeutic human cisatracurium infusions remain well below neurotoxic thresholds.

Clinical Profile: Cisatracurium does not cause histamine release, preserving hemodynamic stability without inducing bronchospasm or peripheral vasodilation. It is the agent of choice for continuous infusion in neurocritical care patients with acute kidney injury ( A K I AKI A K I ) or hepatic dysfunction.

Rocuronium & Vecuronium (Aminosteroids)

Rocuronium: Rapid-onset ( 60 – 90 seconds 60\text{--}90\text{ seconds} 60 – 90 seconds ) intermediate-acting steroidal blocker. Cleared primarily by hepatic uptake and biliary excretion ( > 70 % > 70\% > 70% ), with 20 % – 30 % 20\%\text{--}30\% 20% – 30% excreted unchanged in urine. In severe hepatic cirrhosis, its volume of distribution increases and clearance declines, causing prolonged duration of action. Specifically and rapidly reversed by sugammadex , a modified gamma-cyclodextrin that encapsulates free rocuronium molecules in plasma in a 1 : 1 1:1 1 : 1 ratio.

Vecuronium: Intermediate-acting aminosteroid. Undergoes hepatic deacetylation to 3-desacetylvecuronium , an active metabolite possessing approximately 50 % 50\% 50% of the parent drug's neuromuscular blocking potency. In acute kidney injury or chronic renal failure, 3-desacetylvecuronium accumulates extensively, causing prolonged, unpredictable paralysis lasting days after infusion termination.

  • Clinical Parameter Cisatracurium Rocuronium Vecuronium
  • Chemical Class Benzylisoquinolinium Aminosteroid Aminosteroid

Primary Clearance Organ-independent Hofmann elimination ( 80 % 80\% 80% ) Hepatic uptake & biliary excretion ( 70 % 70\% 70% ) Hepatic metabolism ( 60 % 60\% 60% ), renal excretion ( 40 % 40\% 40% )

Active Metabolites Laudanosine (inactive at clinical doses) None of clinical significance 3-desacetylvecuronium (accumulates in renal failure)

Onset Time 2 – 3 minutes 2\text{--}3\text{ minutes} 2 – 3 minutes 60 – 90 seconds 60\text{--}90\text{ seconds} 60 – 90 seconds 2 – 3 minutes 2\text{--}3\text{ minutes} 2 – 3 minutes

Reversal Options Neostigmine + Glycopyrrolate Sugammadex (immediate) or Neostigmine Sugammadex or Neostigmine

Suitability in AKI First-line (unimpaired clearance) Acceptable (slight prolongation) Avoid (risk of active metabolite toxicity)

Train-of-Four (TOF) Peripheral Nerve Monitoring

Train-of-Four monitoring utilizes a peripheral nerve stimulator delivering four supramaximal electrical impulses at a frequency of 2 Hz 2\text{ Hz} 2 Hz ( 0.2 ms 0.2\text{ ms} 0.2 ms duration each, delivered over 2 seconds). The number of palpable or visible muscle twitches correlates with the fraction of postsynaptic nicotinic acetylcholine receptors occupied by the blocker. Train-of-Four (TOF) Twitch Response & Receptor Occupancy

  • [ | | | | ] 4 Twitches: < 75% Nicotinic Receptors Blocked (No/Minimal Blockade)
  • [ | | | . ] 3 Twitches: ~ 80% Receptors Blocked
  • [ | | . . ] 2 Twitches: ~ 85% Receptors Blocked (Optimal ICU Target)
  • [ | . . . ] 1 Twitch: ~ 90% Receptors Blocked (Optimal ICU Target)
  • [ . . . . ] 0 Twitches: Deep block; receptor occupancy is not proven to be 100%
  • Monitoring Sites & Technical Pitfalls

Ulnar Nerve / Adductor Pollicis: Standard site. Stimulating electrodes are placed along the flexor carpi ulnaris pathway at the wrist; thumb adduction is assessed. The adductor pollicis recovers from blockade later than diaphragm and laryngeal muscles, making it a safe surrogate to prevent premature extubation.

Facial Nerve / Orbicularis Oculi: Electrodes placed on the temple over the temporal branch of the facial nerve; eyelid twitching is observed.

Warning

The Facial Nerve Pitfall: Facial muscles are more resistant to neuromuscular blockade than peripheral extremity muscles and recover faster. Relying solely on facial nerve TOF monitoring frequently leads clinicians to overestimate the requirement for N M B A s NMBAs NMB A s , causing inadvertent drug overdosing and profound diaphragm/skeletal muscle over-paralysis. Always cross-correlate with the ulnar or posterior tibial nerve.

Many ICU protocols use one or two TOF responses as an adjunct, but titrate to the clinical indication and the minimum effective blockade. TOF alone does not measure sedation, prevent every adverse effect, or prove a precise receptor occupancy. Investigate a zero response and adjust according to the treatment goal and protocol rather than reflexively stopping necessary therapy in every case.

Absolute Prerequisite: Deep Analgosedation

NMBAs provide no analgesia, amnesia, or sedation. Establish adequate analgosedation before paralysis and maintain it throughout. RASS cannot be assessed meaningfully during complete paralysis. Processed EEG indices may assist selected monitoring but do not independently guarantee unconsciousness, and burst suppression is not required solely because an NMBA is used.

Complications of Prolonged Neuromuscular Blockade

Critical Illness Myopathy (CIM) & Polyneuropathy (CIP): Prolonged immobility and receptor blockade lead to myosin loss, muscle fiber atrophy, and denervation-like membrane unresponsiveness. Concurrent administration of systemic corticosteroids and N M B A s NMBAs NMB A s synergistically increases the incidence of acute quadriplegic myopathy, causing profound flaccid quadriplegia and ventilator dependence lasting months.

Corneal Ulceration & Exposure Keratopathy: Complete orbicularis oculi paralysis eliminates spontaneous blinking and causes lagophthalmos (inability to fully close the eyelids). Without intervention, rapid corneal desiccation leads to epithelial sloughing, ulceration, and permanent blindness. A mandatory eye-care protocol requiring preservative-free ocular lubricating ointment every 2 to 4 hours and passive eyelid taping is essential.

Decubitus Ulcers & Nerve Compression: Inability to reposition produces ischemic skin breakdown over bony prominences (sacrum, heels, occiput) and compressive neuropathies (peroneal nerve palsy at the fibular head, ulnar nerve palsy at the cubital tunnel). Frequent log-rolling, pressure-relieving air mattresses, and padded positioning are mandatory.